Search
AbbVie to Acquire Capstan Therapeutics for a Potential $2.1 Billion
1 day ago /
Read about 0 minute
Author：小编
On June 30, 2025, AbbVie unveiled its intention to acquire Capstan Therapeutics, a pioneering developer of cellular therapies, for a maximum cash consideration of $2.1 billion. Capstan specializes in the advancement of CAR-T therapies, with its flagship drug, CPTX2309, currently undergoing Phase 1 clinical trials for the treatment of B-cell-mediated autoimmune diseases. This acquisition is poised to significantly bolster AbbVie's research and development pipeline, particularly as the company's blockbuster arthritis drug, Humira, is approaching the expiration of its patent protection. The move underscores AbbVie's strategic commitment to diversifying its business portfolio and sustaining its competitive edge in the industry.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
